

DAY 2 HIGHLIGHT:

A Deeper Dive into Academic Insight

By GBCC Scientific Program Committee

Sang Eun Nam (Konkuk Univ. Medical Center)

Kwan Ho Lee (Kangbuk Samsung Hospital)

Heejung Chae (Seoul National Univ. Bundang Hospital)

Hye Sung Won (The Catholic Univ. of Korea, Uijeongbu St. Mary's Hospital)

Plenary Lecture 3

The ADC Revolution: Shaping the Future of Potent and Precise Cancer Therapy

This session welcomes world-renowned expert Giuseppe Curigliano, MD, PhD, to discuss one of the most dynamic shifts in modern oncology: Next-Generation Antibody-Drug Conjugates (ADCs). It will provide a comprehensive roadmap of the recent progress across all four key components of ADCs—monoclonal antibody, payload, linker, and conjugation chemistry—while extending into an in-depth exploration of emerging ADC formats such as bispecific constructs, conditionally active agents, immune-stimulating ADCs, protein-degrader ADCs and dual-payload systems. Through this session, we anticipate gaining valuable perspectives on patient selection and biomarkers, driving the evolution of safer and more potent ADC therapies for clinical use.

Plenary Lecture 4

What Does it Take to Make Precision Oncology Precise?

We are honored to welcome Laura Esserman, MD, PhD, as our keynote speaker. In this session, she will challenge traditional "one-size-fits-all" approaches, advocating for biology-driven treatment and risk-based screening, and will explore how integrating molecular profiling, adaptive trial designs, and patient-centered data can transform the

standard of care from broad interventions to truly personalized medicine.

General Session 2

Endocrine Refinement, Digital Survivorship, and Personalized Long-Term Care



[GS-05] Clinical Effect of Bisphosphonate in Patients with Hormone Receptor-positive Early Breast Cancer: A Nationwide Real-world Data Analysis

Wonseok Choi (Korea Univ. Guro Hospital, Korea)



[GS-06] A Multidisciplinary Digital Platform to Support Breast Cancer Patients During Adjuvant Treatment: A Pilot Randomized Controlled Trial

Seung Mi Yeo (Pusan National Univ. Yangsan Hospital, Korea)



[GS-07] Efficacy and Patient-reported Outcomes (PROs) of Ribociclib (RIB) + Nonsteroidal Aromatase Inhibitor (NSAI) in Younger Patients (pts) with HR+/HER2-early Breast Cancer (EBC) in NATALEE: a 5-y Update

Seock-Ah Im (Seoul National Univ. Hospital, Korea)



[GS-08] Chemotherapy-Induced Amenorrhea Duration Modifies the Benefit of Ovarian Function Suppression: A Substudy of the ASTRRA Trial

Woong Ki Park (Samsung Medical Center, Korea)

General Session 2 highlights the evolving direction of breast cancer care, from individualized endocrine strategies to stronger survivorship support and more precise long-term treatment planning. Drawing on real-world evidence, trial updates, and digital innovation, the session reflects a more personalized approach to treatment and long-term outcomes.

In this context, bisphosphonates may improve survival in older patients with HR-positive early breast cancer. Similarly, a digital platform improves symptoms, function, and health behaviors during adjuvant treatment. Likewise, five-year NATALEE data support durable ribociclib benefit in younger HR-positive/HER2-negative patients. In addition, ASTRRA refines OFS selection by timing of ovarian recovery after chemotherapy.

Poster Discussion 3, 4

Poster Discussion Sessions Highlight Evolving Strategies in Metastatic Brain Disease, Surgical Outcomes, and Precision Radiotherapy

Presenters explored subtype-specific risks of brain metastases and the safety of combining targeted therapies with radiosurgery to enhance intracranial control. The session also highlighted geometric predictors for optimizing radiotherapy benefits and compared functional recovery between different breast reconstruction techniques.

Overview of Key Programs

A Broad Spectrum of Programs Spanning Care, Research, and Collaboration

Beyond the core scientific sessions, the congress features a diverse lineup of programs designed to address various aspects of breast cancer care and collaboration. The Nursing Session will offer in-depth lectures on nursing care for breast cancer patients, ranging from those who have undergone surgical treatment to those with metastatic or recurrent disease. Similarly, the International Networking Sessions will feature the GBCC–JBCS–TBCS Joint Session, which will discuss the clinical evidence and real-world use of ovarian function suppression across Asia. Likewise, the Junior Doctors Forum and Debate is expected to serve as a platform for research collaboration and knowledge exchange among young physicians who treat breast cancer patients.

In addition, four Education Sessions will cover a wide range of topics related to axillary care. Additionally, five Symposia will address the latest advances in systemic therapy, biomarker-driven treatment, and de-escalation of breast cancer surgery. Finally, the expanding role of AI in breast imaging and treatment will be discussed in a Multidisciplinary Session and Symposium 6.